The Motley Fool

2 opportunities to beat the FTSE 100 which won’t last forever

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Beating the FTSE 100 over a long period is never an easy task. Certainly, it is very possible to do so over a short-term timeframe, but to do so consistently requires skill and an ability to remain disciplined in a variety of market conditions.

At the present time, many stocks are trading at record highs after a period of strong performance. The index is close to breaking through a new record, and this means that there may be a lack of value in many parts of the market. However, here are two stocks which have fallen in recent months and that could therefore offer a wide margin of safety for the long run.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

Improving outlook

Reporting on Tuesday was veterinary pharmaceuticals specialist Dechra (LSE: DPH). The company’s performance in the first half of its financial year has been in line with management expectations. Reported revenue increased by 10.5% at constant exchange rates, with its European Pharmaceuticals revenue growth being 5.5% at constant currency. In North America, its Pharmaceuticals revenue growth was 20% at constant currency, while it was able to complete the bolt-on acquisition of RxVet Limited.

In the last three months the share price of Dechra has fallen around 7%. That’s despite the company continuing to offer an upbeat earnings growth outlook. It is forecast to post a rise in its bottom line of 12% in the current financial year. At a time when a number of pharmaceutical majors are struggling to post above-average earnings growth figures, this could appeal to investors and help to drive the company’s share price higher.

Dechra also has a solid track record of earnings growth. The company has been able to grow its net profit at an annualised rate of 25% during the last five years. This shows that it may offer high and consistent performance in the long run.

Potential turnaround

Also seeing its share price fall in recent months has been oil and gas support services company Petrofac (LSE: PFC). Its shares are down 44% in the last year due in part to the impact of the SFO (Serious Fraud Office) investigation into the company. This has been ongoing for many months and has caused investors to remain cautious about the future prospects for the business.

However, after its share price fall, Petrofac now appears to offer a wide margin of safety. It has a price-to-earnings (P/E) ratio of around 9.4, which suggests that the stock market has priced-in potential difficulties for the business. And with a dividend yield of 5.2% which is covered 2.1 times by profit, the prospects for a high total return seem significant.

Certainly, the stock is relatively high-risk. The SFO investigation could cause further falls in its share price, while continued difficulties in the oil and gas industry may do likewise. However, with such a low valuation, it could also offer high rewards in the long run.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Peter Stephens owns shares of Petrofac. The Motley Fool UK owns shares of Petrofac. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.